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Abstract
Background: We aimed to analyze the differences in the prevalence of outer retinal tubulation (ORT) in
neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-
VEGF) agents, either aflibercept or ranibizumab. Our further aim was to examine the changes in the frequency of
injections of ranibizumab before and after ORT appearance.
Methods: Two hundred thirty six eyes of 230 patients were included in the study (184 eyes treated with
ranibizumab by pro re nata regimen (PRN), 52 eyes with aflibercept bimonthly) and followed for 6–24 months.
Using optical coherence tomography (OCT), the first appearance of ORT was documented, and fixed time point
evaluations were also made every six months to determine the existence of ORT. The number of injections, the
presence or absence of subretinal hyperreflective material (SHRM) at treatment initiation and visual acuity were also
noted.
Results: The survival analysis with Cox proportional hazard model showed no significant difference between the
ranibizumab and aflibercept groups in relation to the development of ORT (p = 0.79, hazard ratio 0.92). In the PRN
treated ranibizumab group the number of injections showed significant decrease after ORT development (p = 0.004).
When SHRM was present at treatment initiation the chance of developing ORT was 2.75 and 11.14 times higher in the
ranibizumab and aflibercept groups, respectively.
Conclusions: The prevalence of ORT increased over time independently from the chosen anti-VEGF drug. Our results
suggest that upon the appearance of ORT a decrease in retreatments can be expected.
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Background
Outer retinal tubulation (ORT) is a spectral-domain op-
tical coherence tomography (SD-OCT) biomarker [1], first
described by Zweifel et al. [2]. They defined ORTs as
hyporeflective, branching tubular structures with hyperre-
flective borders within the outer nuclear layer of the retina
[2]. The “en face” OCT technique can help map these
branching networks [3]. ORTs have been observed in
many retinal diseases, including exudative age-related
macular degeneration (AMD) [2]. Based on histological
reports, the border of the outer retinal tubulation consists
of photoreceptor inner segment mitochondria and exter-
nal limiting membrane (ELM), with fluid and photorecep-
tor outer segments being potentially present in the ovoid
hyporeflective lumen of the ORT [4–6]. Adaptive optics
scanning laser ophthalmoscopy findings are in correlation
with histology reports and show lack of ORT cone
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reflectivity which can be due to the loss of cone outer seg-
ments and subsequent retinal remodeling [7].
Schaal et al. classified outer retinal tubulations as
either open (incomplete closure with curving external
limiting membrane at the ends, horizontally elongated
shape in cross-section) or closed (completely encircled,
oval shape in cross-section) ORTs [4].
ORT can be mistaken for intraretinal cysts, or subretinal
fluid but with the recognition of its hyperreflective border
and special occurrence in the outer nuclear layer these
mistakes can be reduced, leading to a reduction in the rate
of anti-VEGF overtreatment in exudative AMD [2].
The ORT prevalence in exudative AMD is low at the
time of first diagnosis but over time during anti-VEGF ther-
apy its prevalence increases [8, 9]. The importance of ORT
as an OCT biomarker for photoreceptor degeneration is
due to its connection with reduced visual acuity [1, 8–10].
It has been also reported that ORTs develop above areas
of subretinal hyperreflective material (SHRM) or atrophy
[8, 9]. SHRM is a medium- to hyperreflective mass be-
tween the neurosensory retinal layers and retinal pigment
epithelium on OCT [11]. It usually represents either a type
II choroidal neovascular complex or is the consequence of
an active choroidal neovascularisation, including subretinal
haemorrhage and lipid or fluid exudation [1, 11, 12].
The aim of the present study was to investigate the
prevalence of ORTs in eyes with neovascular AMD
undergoing treatment either with ranibizumab or afliber-
cept. Our further aim was to examine the changes in the
frequency of injections before and after ORT appearance.
We also assessed the presence of subretinal hyperreflec-
tive material and its relationship with ORT.
Methods
Ethics, consent
This retrospective study was performed at the Medical
Retina Unit of the Ophthalmology Department of
University of Szeged, in Hungary. The study was ap-
proved by the Institutional Review Board of University of
Szeged Albert Szent-Györgyi Clinical Centre (reference
number: 3650) and was in accordance with the ethical
standards of the Declaration of Helsinki. Since this was a
retrospective review of patient data, informed consent was
not required. The need for a consent was formally waived
by the ethics committee, and this was also in line with the
national regulations.
Patients
Treatment-naïve exudative AMD patients were enrolled
in the study. For the ranibizumab group enrollment took
place between October 2014 to April 2016 while patients
in the aflibercept group were enrolled between April
2015 to April 2016.
All patients were over 50 years of age, the mean
follow-up period was 16.3 months and 9.2 months (range
6–24 months and 6–12 months) in the ranibizumab and
aflibercept groups, respectively.
During each visit a comprehensive ophthalmic examin-
ation was carried out including best-corrected visual acuity
(BCVA, Early Treatment Diabetic Retinopathy Study
(ETDRS) score) assessment, slit-lamp biomicroscopy,
dilated funduscopy and SD-OCT examination of the
retina (Heidelberg Spectralis, Heidelberg Engineering,
Heidelberg, Germany). Eyes with poor quality SD-OCT
scans (Q index below 20) or with poor compliance were
excluded from the study (14 eyes from the ranibizumab
and 3 eyes from the aflibercept group).
Treatment regimen for both ranibizumab (0.5 mg) and
aflibercept (2 mg) started with 3 monthly injections.
After this initiation phase the ranibizumab group was
treated by a pro re nata (PRN) regimen with follow-up
visits scheduled monthly. The retreatment criteria for
ranibizumab patients consisted of any subretinal or
intraretinal fluid on OCT, or new haemorrhage on fun-
duscopy. In the aflibercept group follow-up after the
loading phase was scheduled every two months, treat-
ment was given at each follow-up. The above regimens
were in accordance with the available treatment guide-
lines in Hungary at the time of the study.
For SD-OCT imaging a pattern size of 5.8 × 5.8 mm,
20° × 20° was applied with 25 B-scans, using the “fol-
low-up” mode. By manual review of the scan volumes
we determined the first appearance of the ORT in both
groups. We also assessed the presence of ORT at fixed
time points at baseline, month 6 and 12 in both groups
and at months 18 and 24 in the ranibizumab group. Im-
ages were assessed by two independent retina specialists,
in case of incongruity the images were referred to a third
retina specialist to make a decision. During the evalu-
ation of OCT scans we did not differentiate between the
above described open (incomplete hyperreflective ring)
and closed (complete hyperreflective ring) forms of ORT
according to Schaal [4]. Thus, both types of ORT detected
on the images were considered an ORT positive case. The
criterion of ORT was a hyperreflective ovoid-elongated
structure in the outer nuclear layer of the retina with
lower reflective content (Fig. 1).
The readers also identified the presence or absence of
subretinal hyperreflective material on SD-OCT images
at treatment initiation. The criterion for SHRM was a
medium- to hyperreflective mass between the neurosen-
sory retinal layers and retinal pigment epithelium, as
described by Keane et al. [11] (Fig. 1).
Statistical methods
The BCVA was compared across the two groups using
the Mann-Whitney U-test. The survival analysis for
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ORT development was analyzed by a Cox proportional
hazard model. We analyzed the correlation between the
presence of SHRM at treatment initiation with the de-
velopment of ORT by Chi-square test and calculated
relative risks. Where zeros were involved for the compu-
tation of relative risk, 0.5 was added to all cells, accord-
ing to the previous suggestions [13].
The injection rate was calculated only in the PRN
treated ranibizumab group due to the fixed 2 month
therapeutic regimen of aflibercept. We assessed the in-
jection rate only before and after the appearance of
outer retinal tubulation and compared using the the
Mann-Whitney U-test. In order to correct bias due to
the unequal follow-up time (some patients had a higher
number of injections due to the longer follow-up), we
divided the follow-up time with the number of injections
and calculated with monthly injections.
A p-value of p < 0.05 was taken as statistically significant.
For the analyses the IBM SPSS Software (Version 22)
was used.
Results
In the ranibizumab group we evaluated 184 eyes of 179
patients, with a median age of 74 years (range 51 to 88),
while in the aflibercept group there were 52 eyes of 51
patients with a median age of 75 years (range 58 to 87).
The mean baseline best corrected visual acuities in the
two groups were (mean ± SD) 59.16 ± 13.9 (median 61)
and 53.96 ± 13.54 (median 55.5) ETDRS letters in the
ranibizumab and aflibercept group, respectively. There
was no significant difference between the two groups
(Mann-Whitney U-test p = 0.083). The BCVA at the
end of the follow-up was 57.19 ± 20.19 (median 63)
and 59.46 ± 15.54 (median 64) ETDRS letters in the
ranibizumab and aflibercept group, respectively. There
was no significant difference between the two groups
(Mann-Whitney U-test p = 0.69).
Table 1 shows the number of eyes during the follow-up
in the two groups. The number of eyes was reduced over
time due to gradual enrollment in the study, thereby not
every patient reached the same follow-up time. In the
ranibizumab group outer retinal tubulation was observed
in 17.4% of cases at baseline, in 33.7% of cases at month 6,
in 45.3% of cases at month 12, and in 55.3% and in 60.8%
of cases at months 18 and 24, respectively. The ORT
prevalence in the aflibercept group was 23.1% at baseline,
40.4% at month 6, and 50% at month 12.
The survival analysis showed no significant difference
between the ranibizumab and aflibercept treated groups
in terms of ORT development. (p = 0.79, hazard ratio
0.92, 95% confidence interval 0.500–1.693) (Fig. 2).
The injection rates showed that the mean injection num-
ber per month before the ORT appearance was 0.37 ± 0.17
while after the ORT development it decreased to
0.21 ± 0.17 (Mann-Whitney U-test p = 0.004).
The presence of subretinal hyperreflective material at
treatment initiation in the two subgroups was 75.5% in
the ranibizumab, and 80.8% in the aflibercept group. In
Fig. 1 Outer retinal tubulations and subretinal hyperreflective material on an SD-OCT single B-scan. Open and closed ORTs in cross section
(left and right solid arrows) above subretinal hyperreflective material (dash arrow). The definition of ORT was a hyperreflective ovoid-elongated
structure in the outer nuclear layer of the retina with lower reflective content
Table 1 Number of eyes reaching the follow-up in the
ranibizumab and aflibercept treated groups
Ranibizumab Aflibercept
Time point n (eyes) n (eyes)
Baseline 184 52
at 6 months 184 52
at 12 months 161 28
at 18 months 103 0
at 24 months 51 0
Table legend: The column with “n” corresponds to the number of eyes
reaching the follow-up
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the ranibizumab treated group ORT developed in 85
eyes of 139 eyes with SHRM (61.15%), while without
SHRM (45 eyes) ORTs were found merely in 10
eyes (22.2%) corresponding to a relative risk of
2.75. (p < 0.01). In the aflibercept treated group 55.81%
of eyes with SHRM developed ORT (24 eyes of 43). No
ORT developed in the eyes without SHRM (out of 9 eyes),
consistent with a relative risk of 11.14 (p < 0.01).
Discussion
Our study found no significant difference between the
ranibizumab and aflibercept treated groups according to
ORT development. There was a statistically significant
reduction in the frequency of injections in the ranibizu-
mab treated group before and after ORT appearance.
The presence of SHRM at treatment initiation as a bio-
marker had a statistically significant correlation with the
development of ORT in both groups.
Zweifel first described outer retinal tubulation in 2009
[2]. Later the authors reported ORTs in various retinal dis-
orders like neovascular AMD, geographic atrophy, polypoi-
dal choroidal vasculopathy, non-AMD associated choroidal
neovascularisation, and other degenerative retinal disorders
(e.g. retinitis pigmentosa, gyrate atrophy, choroideremia,
Stargardt disease, pattern dystrophy) [2, 3, 14–19].
The pathogenesis of ORT formation is still not com-
pletely clear, though recent reports helped a lot explor-
ing it. Dolz-Marco et al. called the attention on the role
of Müller cells in the pathomechanism of ORT develop-
ment, namely the progressive photoreceptor damage
that can result in Müller cell activation which thereby
starts to produce glial fibrillary acidic protein, facilitating
the formation of ORT [20]. Based on histological exami-
nations it seems that the evolution of ORT starts with
ELM and ellipsoid zone disruption [4]. ELM starts to
scroll inward at its free edges, representing an initial
form of ORT, leading to the development of a formed
open ORT. With time the large, open ORTs split, their
margins beginning to scroll ending in multiple smaller
closed ORTs. During the scrolling process a downward
displacement of adjacent inner nuclear layer and outer
plexiform layer happens separating each ORT, and caus-
ing the appearance of microcystic lesions in the inner
nuclear layer. The downward displacement of these
layers might be due to the involvement of Müller cells in
this scrolling/dragging process as Müller cells are con-
tributing to the constitution of ELM with the inner
segments of photoreceptors [4, 15, 20, 21].
Most of the studies in the field focused on exudative
AMD and its relationship with ORT. From these reports
it is known that ORT is an SD-OCT biomarker, the
prevalence of which increases with time and is associ-
ated with decreased visual acuity [1, 8, 9]. It has been
also reported that ORTs develop adjacent to areas of
subretinal hyperreflective material or atrophy [8, 9]. The
differential diagnostic importance of outer retinal tubu-
lation lies in the avoidance of overtreatment due to its
similarity to intraretinal fluid [2, 8].
In the present study, we evaluated treatment-naïve ex-
udative AMD patients treated with ranibizumab and
Fig. 2 Cox proportional hazard model of ORT survival in the ranibizumab and aflibercept groups
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aflibercept regarding the presence of outer retinal tubula-
tion. Altogether 236 eyes were followed in both groups
with no statistical difference between the baseline charac-
teristics of the two groups considering age and BCVA.
The prevalence of ORT continuously increased during
the follow-up period, in both groups. In the ranibizumab
group its prevalence almost quadrupled at the 24-month
follow-up, while there was a doubling in the aflibercept
group in 12 months. It is important to note, that in the
ranibizumab group the baseline prevalence was lower
(17.4% versus 23.1%). Dirani et al. found a similar in-
creasing trend in their study starting with 2.5% at pres-
entation, reaching 41.6% at 4 years of follow-up [8]. In
our study the baseline ORT prevalence was higher com-
pared to other reports [8, 9]. The reason behind this
could be the more advanced disease state at the time of
presentation (due to the real life nature of our retro-
spective study) and a relative delay in therapy initiation
due to country-specific financial difficulties. The poorer
baseline BCVA in both groups also supports this idea.
There is one previous article known, describing ORT
development in 24 non-treatment-naïve eyes, treated
with aflibercept only after receiving at least 6 ranibizu-
mab injection, reporting an initial 97% ORT prevalence
which later decreased to 75% [22].
To our knowledge, our study is the first to report re-
sults in treatment naïve patients treated with aflibercept
and its connection with ORT development. The Cox
proportional hazard model analysis suggested that there
was no difference between the two in-label therapies
ranibizumab and aflibercept in regard to the prevalence
of outer retinal tubulation. Lee et al. in the Comparison
of AMD Treatment Trials (CATT) study group evalu-
ated the prevalence of ORTs in ranibizumab and bevaci-
zumab treated neovascular AMD patients, and found no
difference between the two drugs related to the preva-
lence of outer retinal tubulation [9].
In the present study we found a statistically significant
difference in the monthly injection rate before and after
the appearance of outer retinal tubulation in the ranibizu-
mab treated group. Our results suggest that in patients
who develop ORT a decrease in the retreatment rate can
be expected which may be a very important clinical
marker. Although we had a PRN regimen according to the
Hungarian guidelines, Lee et al. found no difference be-
tween the fixed monthly regimen versus PRN regimen in
regards to ORT development in patients treated either
with ranibizumab or bevacizumab [9].
We found a statistically significant connection between
ORT development and the presence of subretinal hyper-
reflective material at treatment initiation. When subret-
inal hyperreflective material was present the chance of
developing ORT was 2.75., and 11.14 higher in the
ranibizumab and aflibercept groups, respectively, in
accordance with the results of Lee et al. in ranibizumab
and bevacizumab treated patients [9].
Our findings, in concordance with the above mentioned
study results suggest that ORT is independent of the
chosen anti-VEGF drug or the dosing regimen of intravit-
real anti-VEGF treatment. The appearance of ORT suggests
that the clinicians can expect a decrease in the number of
injections when following a pro re nata ranibizumab regi-
men. Our fixed bimonthly treatment with aflibercept did
not allow us to analyze the injection rate before and after
ORT development in this group. Our study also supports
the previously reported higher prevalence of ORT develop-
ment in the presence of subretinal hyperreflective material
at treatment initiation [9].
There is a number of limitations of our study. Namely,
the relatively small sample size in the aflibercept group
compared to the ranibizumab group, along with the bi-
monthly follow-up in the aflibercept group. We believe
that the number of subjects involved in both groups is
comparable with other studies published in the field, while
the bimonthly treatment regimen with aflibercept was
fixed due to the country-specific guideline regulations.
The decreasing number of eyes during the follow-up
could also bias the analysis by including patients with
increasing disease severity. However, we believe these fac-
tors were similar to those in similar studies available in
the field. The strength of this report is the comparison of
present in-label therapies, ranibizumab and aflibercept in
exudative AMD patients in relation to ORT besides the
evaluation of the injection rate in association with outer
retinal tubulation. We used real life data that makes the
study more relevant in the daily clinical practice.
Conclusions
The development of ORT could be a potential biomarker for
the treatment prognosis in patients with wet AMD. Its clin-
ical significance lies also in its similarity to activity-related
intraretinal fluid. Further studies are needed to explore the
nature and development of ORTs employing a comparable
dosing and follow-up regimen of all three currently available
anti-VEGF drugs ranibizumab, bevacizumab and aflibercept.
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